Aktis Oncology, Inc.


Aktis Oncology is dedicated to transforming cancer care through the development of novel platform technologies that enable the design and development of powerful precision radiopharmaceuticals. These targeted therapies harness the superior anticancer potency of alpha-emitting particles to impact tumors with currently limited treatment options, aiming to improve outcomes and achieve higher cure rates for solid cancers.

Industries

biotechnology
health-care
life-science
oncology

Nr. of Employees

small (1-50)

Aktis Oncology, Inc.

17 Drydock Avenue, Suite #17-401, Boston, MA 02210


Patents

Nectin-4 binding miniproteins, conjugates and uses thereof

US-12427212-B2

View Details

Products

Radiopharmaceuticals

Aktis Oncology develops alpha-emitting radiopharmaceuticals that target and destroy cancer cells while minimizing harm to healthy cells.

Nectin-4 Targeting Program

A clinical-stage program focused on targeting Nectin-4, a protein found in various cancers, to deliver alpha radiotherapy.

Pipeline of Targeting Molecules

Aktis Oncology is developing a pipeline of seven proprietary programs aimed at delivering alpha radiotherapy to a range of cancers including breast, lung, colorectal, bladder, and liver cancers.

Theranostic Approach

Aktis Oncology uses imaging tools to visualize and verify tumor target engagement, allowing better prediction of patient response to radiopharmaceutical therapy.

Manufacturing and Delivery

Aktis Oncology ensures just-in-time delivery of radiopharmaceuticals by managing the entire manufacturing process to maintain drug efficacy.


News & Updates

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.